Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.

Front Oncol · 2021 · PMC8655309 · PMID 34900718

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

did not reach statistical significancep = 0.11not close (p > 0.1)

At interim analysis, the median OS was longer in the talazoparib arm (22.3 months) than in the chemotherapy arm (19.5 months), but it did not reach statistical significance (HR: 0.76; 95% CI, 0.55–1.06, p = 0.11).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.